VISIPAQUE™ (iodixanol) Injection, 5,5'-[(2-hydroxy-1,3-propanediyl)bis (acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6- triiodo-1,3- benzenedicarboxamide], is a dimeric, isosmolar, nonionic, water-soluble, radiographic contrast medium with a molecular weight of 1550.
VISIPAQUE Injection (270 mgI/mL) is indicated for intra-arterial digital subtraction angiography.
VISIPAQUE Injection (320 mgI/mL) is indicated for angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography.
INTRAVENOUS For information on the concentrations and doses for the pediatric population see the Precautions–Pediatric Use, Clinical Pharmacology–Special Populations, and Dosage and Administration sections.
VISIPAQUE Injection (270 mgI/mL) is indicated for CECT imaging of the head and body, excretory urography, and peripheral venography.
VISIPAQUE Injection (320 mgI/mL) is indicated for CECT imaging of the head and body, and excretory urography.
Media Articles Related to Visipaque (Iodine Intravascular)
Study examines type of exome sequencing and molecular diagnostic yield
Source: Genetics News From Medical News Today [2014.10.21]
In a sample of patients with undiagnosed, suspected genetic conditions, a certain type of exome sequencing method was associated with a higher molecular diagnostic yield than traditional molecular...
Whole-exome sequencing shows potential as diagnostic tool
Source: Genetics News From Medical News Today [2014.10.21]
Among a group of 2,000 patients referred for evaluation of suspected genetic conditions, whole-exome sequencing provided a potential molecular diagnosis for 25 percent, including detection of a...
Stroke Rounds: Best PFO Diagnostic With Lung Clots?
Source: MedPage Today Neurology [2014.10.16]
(MedPage Today) -- Is there a best way to find patent foramen ovale (PFO)?
Nanodevices for clinical diagnostic with potential for the international market
Source: Blood / Hematology News From Medical News Today [2014.10.15]
In order to obtain accurate and immediate diagnosis, a group of researchers in the area of Nano-Optics at the Center for Scientific Research and Higher Education of Ensenada, Baja California...
Making diagnostic medical imaging safer
Source: MRI / PET / Ultrasound News From Medical News Today [2014.10.01]
Medical imaging is at the forefront of diagnostics today, with imaging techniques like MRI (magnetic resonance imaging), CT (computerized tomography), scanning, and NMR (nuclear magnetic resonance)...
Published Studies Related to Visipaque (Iodine Intravascular)
Alcohol-based chlorhexidine vs. povidone iodine in reducing skin colonization prior to regional anesthesia procedures. [2011.07]
CONCLUSION: For skin disinfection prior to the neuraxial blockade procedure, the use of alcohol-based chlorhexidine compared with the use of povidone iodine lowered the incidence of insertion-site-colonization.
MDCT angiography for detection of pulmonary emboli: comparison between equi-iodine doses of iomeprol 400 mgI/mL and iodixanol 320 mgI/mL. [2009.06]
OBJECTIVES: To compare iomeprol 400 and iodixanol 320 in pulmonary artery MDCTA in subjects with suspected pulmonary embolism... CONCLUSION: The greater iodine delivery rate achievable with iomeprol 400 compared to iodixanol-320 at equi-iodine dose and injection rate permits consistently greater attenuation at all levels of the pulmonary arterial tree.
Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. [2006.09.05]
OBJECTIVES: This study sought to compare the nephrotoxicity of iodixanol and ioxaglate in patients with renal impairment undergoing coronary angiography. BACKGROUND: Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium (IOCM), may be less nephrotoxic than low-osmolar contrast media (LOCM) in high-risk patients... CONCLUSIONS: The IOCM iodixanol was significantly less nephrotoxic than ioxaglate, an ionic, dimeric LOCM. (The RECOVER Trial; http://clinicaltrials.gov; NCT00247325).
Intravenous contrast material administration at helical 16-detector row CT coronary angiography: effect of iodine concentration on vascular attenuation. [2005.08]
The institutional review board approved this study, and all patients gave written informed consent. One hundred twenty-five patients scheduled to undergo retrospectively electrocardiographically gated 16-detector row computed tomographic coronary angiography were prospectively randomized into the following five groups with respect to the intravenous administration of a 140-mL bolus of contrast material at 4 mL/sec: group 1 (iohexol [300 mg of iodine per milliliter]), group 2 (iodixanol [320 mg I/mL]), group 3 (iohexol [350 mg I/mL]), group 4 (iomeprol [350 mg I/mL]), and group 5 (iomeprol [400 mg I/mL])...
Reduced Iodine Load at CT Pulmonary Angiography with Dual-Energy Monochromatic Imaging: Comparison with Standard CT Pulmonary Angiography--A Prospective Randomized Trial. [2011.11.14]
Purpose:To compare quantitative and subjective image quality and radiation dose between standard computed tomographic (CT) pulmonary angiography (CTPA) and CTPA with a dual-energy technique with reduced iodine load.Materials and Methods:This prospective study was approved by the institutional review board and each participant provided informed consent...
Clinical Trials Related to Visipaque (Iodine Intravascular)
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography [Recruiting]
It is well known that X-ray contrast media can affect kidney function in some patients,
especially when administered intra-arterially, and patients who already suffer from reduced
kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use
low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast
media-induced nephropathy. However, little is known about the intravenous use of X-ray
contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose
of this study is to evaluate and compare the effects on kidney function of two contrast
media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney
damage associated with the injection of contrast media. Due to the iso-osmolar feature, it
is expected less influence on renal function following administration of iodixanol. A
standard hydration procedure, based on available guidelines will be given to all patients to
prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be
measured before and up to 7 days after contrast media administration to evaluate the effects
on renal function.
Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients [Recruiting]
The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN)
following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque
320) in patients with chronic kidney disease undergoing coronary angiography.
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography [Recruiting]
The purpose of this study is to evaluate and compare overall patient comfort profile between
an Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast
media (LOCM), iopamidol 370 mg I/mL in patients undergoing arteriography of peripheral
RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography [Completed]
In the treatment of coronary heart disease which is the major cause of heart attack, direct
mechanical treatment with catheters such as the coronary angiography,coronary balloon
intervention and stenting intervention are the mainstay of therapy in recent years. In that
procedures, we should use the contrast media, and it may cause kidney toxicity especially in
the patients with underlying kidney disease and decreased kidney function. We intended to
find out which contrast agent has less kidney toxicity in the catheter based treatment of
coronary arterial diseases in patients with underlying decreased kidney function
A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients [Recruiting]
The investigators intend to find out which contrast agent has less kidney toxicity in renal
impaired patients undergoing cardiac angiography or percutaneous coronary intervention
Reports of Suspected Visipaque (Iodine Intravascular) Side Effects
Renal Failure Acute (10),
Infusion Site Extravasation (7),
Lactic Acidosis (6),
Abdominal Pain (5),
Confusional State (5), more >>
Page last updated: 2014-10-21